Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal
Executive Summary
Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.
You may also be interested in...
Senate Finance Panel’s New Legislative Staffer Kaltenboeck Likes QALYs For Valuing Drugs
Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.
Price Arbitration In Medicare: MedPAC Supportive But Congress Running Out Of Time
In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.
Part D Brand Discounts May Be More Useful In Catastrophic Phase, House Panel Told
Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.